Barr Laboratories Inc. will soon hold the exclusive rights to Loestrin (norethindrone acetate and ethinyl estradiol) and Loestrin FE (norethindrone acetate and ethinyl estradiol/ferrous fumarate) oral contraceptive products in the United States and Canada, thanks to a proposed agreement signed by Barr and the Northern Ireland-based Galen Holdings PLC. The agreement also would settle litigation between the two companies over Galen's femhrt hormone therapy and Estrostep oral contraceptives (both containing norethindrone acetate and ethinyl estradiol). The resolution of the litigation would allow Barr to speed up the availability of a generic version of those products, launching its generic drug 6 months before the Galen patent expires. The two companies expect to finalize the agreement at the end of the year. "This is a good deal for both companies," says Galen's chief executive office Roger Boissonneault.
COPYRIGHT 2003 International Medical News Group
COPYRIGHT 2003 Gale Group
Contact
Home
A
E-Base